Immune-Mediated Diseases in Dogs: Welfare Considerations
Immune-mediated diseases—where the immune system attacks the dog's own tissues—are a major source of welfare compromise in companion dogs. This page reviews key conditions, welfare impacts, treatment approaches, and quality-of-life management.
Overview of Immune-Mediated Disease
Immune-mediated diseases occur when the immune system aberrantly targets self-tissues. Major conditions in dogs include: immune-mediated haemolytic anaemia (IMHA), immune-mediated thrombocytopenia (ITP), immune-mediated polyarthritis (IMPA), pemphigus foliaceus (skin), masticatory muscle myositis (MMM), and immune-mediated meningitis/meningoencephalitis. These conditions vary from highly treatable to life-threatening. Genetic predispositions exist in several breeds.
IMHA: Welfare Impact and Treatment
IMHA is one of the most welfare-significant and life-threatening immune-mediated diseases. Rapid destruction of red blood cells causes severe anaemia, lethargy, exercise intolerance, pale mucous membranes, tachycardia, and—in severe cases—collapse. Blood transfusions are often required for survival. Immunosuppressive therapy (prednisolone, mycophenolate, ciclosporin) must be initiated promptly. Mortality rates of 20–50% are reported even with treatment. Survivors often require long-term medication with associated side effects.
Immune-Mediated Arthritis
IMPA causes polyarthritis—inflammation of multiple joints simultaneously—with lameness, stiffness, joint swelling, and fever. Unlike infectious arthritis, IMPA does not involve joint infection. Welfare compromise includes chronic pain, reluctance to exercise, and in severe cases, joint destruction. Treatment with corticosteroids typically produces rapid improvement; long-term immunosuppression may be required for erosive forms. Pain assessment and quality-of-life monitoring are essential throughout treatment.
Skin Conditions: Pemphigus
Pemphigus foliaceus is the most common autoimmune skin disease in dogs, causing crusty, scaly lesions particularly around the face, ears, and feet. Secondary bacterial infection is common. The condition is uncomfortable, affects body image integrity, and may impair normal behaviour. Immunosuppressive therapy produces remission in most cases, but long-term management is frequently required. Welfare assessment should include evaluation of pruritus, pain from crusting lesions, and effects of medication.
Masticatory Muscle Myositis
MMM causes acute swelling and pain of the jaw muscles (early phases) followed by fibrosis and restricted jaw opening (chronic phases). Dogs in the acute phase cannot open their mouths normally—affecting eating, drinking, play, and normal social behaviour. Early high-dose corticosteroid treatment is essential to prevent permanent fibrosis. Dogs presented late with severely restricted jaw opening have very limited treatment options and significant long-term welfare compromise.
Steroid Side Effects as Welfare Issues
Long-term corticosteroid use—the mainstay of most immune-mediated disease treatment—has significant welfare costs: polyuria/polydipsia, increased hunger (leading to distress if intake is restricted), weight gain, muscle wasting, hepatopathy, and behavioural changes (anxiety, irritability, restlessness). Welfare monitoring must account for medication side effects, not only the primary disease. Steroid-sparing agents (mycophenolate, azathioprine, ciclosporin) can reduce steroid dose and associated welfare burden.
Quality-of-Life Monitoring
Dogs with chronic immune-mediated disease require ongoing quality-of-life assessment. Validated tools (HHHHHMM scale, Lincoln Memorial Veterinary Quality of Life Index) provide structured frameworks. Key domains include: pain, appetite, mobility, engagement with play and social interaction, and absence of distress. Owners should be supported in recognising deterioration and making end-of-life decisions without guilt when quality of life becomes unsustainable despite treatment.
Summary
Immune-mediated diseases represent a major welfare category in companion dogs, combining acute life-threatening crises with chronic management challenges. Optimal welfare requires prompt diagnosis, aggressive initial treatment, monitoring for treatment side effects, and structured quality-of-life assessment throughout the disease course. Owner education, clear communication about prognosis, and ongoing veterinary support are essential for navigating these complex, often lifelong conditions.